Abstract 1063P
Background
There are limited published real-world data on the treatment patterns and outcomes of patients with mCSCC.
Methods
This retrospective study was conducted using IBM MarketScan® Commercial and Medicare databases (1 Jan 2013‒31 Jul 2019). We identified patients ≥18 years of age with a CSCC diagnosis initiating systemic treatment at index date between 1 Jan 2014 and 31 Dec 2018, and who were continuously enrolled for ≥12 months prior to the index date. Eligible patients had evidence of mCSCC during the baseline period; no surgery or radiotherapy (RT) on or 90 days after index date; <3 claims diagnostic codes of lung, head and neck or anogenital squamous cell carcinomas 180 days prior to the index date; and no immunotherapy during follow-up (FU). FU was from the index date to disenrollment, death or end of study.
Results
A total of 207 patients met the inclusion criteria. Mean (standard deviation [SD]) age was 64.8 (13.4) years; 76.3% were male; 59.4% had prior radiotherapy; and 58.9% had prior CSCC related surgery. Mean (SD) FU time was 16.3 (14.3) months. During FU, 75.4%, 51.7% and 36.2% of patients received chemotherapy, RT, or targeted therapy as first-line (1L) treatment. Mean (SD) of duration of 1L therapy was 61.6 (66.5) days. Cisplatin (32.9%) and carboplatin (22.7%) were the most common chemotherapy agents and cetuximab (32.4%) the most common targeted therapy. Median (95% confidence interval) overall survival (OS) as observed during the FU period was 12.1 months (10.4–16.8). OS at 6 and 12 months were 76% and 50%, respectively. In the FU period, 98.6% patients had a CSCC-related outpatient (OP) visit. Mean (SD) CSCC-related healthcare costs in the FU period were $5,354 ($8,945) per person per month (PPPM), with 96.4% attributable to OP costs. Mean (SD) OP costs for RT were $1,589 ($3,374) PPPM. Mean (SD) OP ($31 [$109] PPPM) and inpatient ($23 [$243] PPPM) surgical procedure costs were low.
Conclusions
During the period of this analysis, cisplatin and cetuximab were the most common systemic therapies used in the 1L setting. The prognosis of patients with mCSCC was generally poor. Most CSCC related healthcare costs were due to OP costs.
Clinical trial identification
Editorial acknowledgement
Medical writing support was provided by Emmanuel Ogunnowo, PhD, of Prime, Knutsford, UK, funded by Regeneron Pharmaceuticals, Inc. and Sanofi.
Legal entity responsible for the study
Regeneron Pharmaceuticals, Inc. and Sanofi.
Funding
Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure
E. Ruiz: Financial Interests, Personal, Other, Consulting fees: PellePharm, Sanofi, Regeneron Pharmaceuticals, Inc and Leo Pharmaceuticals; Financial Interests, Personal, Advisory Board, Consulting and advisory board: Checkpoint Therapeutics. C. Chen: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc.. N.M. Zimmerman: Financial Interests, Personal, Full or part-time Employment: IBM Watson Health. G. Konidaris: Financial Interests, Personal, Full or part-time Employment: Sanofi; Financial Interests, Personal, Stocks/Shares: Sanofi. X. Song: Financial Interests, Personal, Full or part-time Employment: IBM Watson Health.